These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36445458)

  • 1. Prevalence trends and individual patterns of ADHD medication use in pregnancy in Norway and Sweden, 2010-2019.
    Cohen JM; Srinivas C; Furu K; Cesta CE; Reutfors J; Karlstad Ø
    Eur J Clin Pharmacol; 2023 Jan; 79(1):173-180. PubMed ID: 36445458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in use of attention deficit hyperactivity disorder medication among children and adolescents in Scandinavia in 2010-2020.
    Sørensen AMS; Wesselhöeft R; Andersen JH; Reutfors J; Cesta CE; Furu K; Hartz I; Rasmussen L
    Eur Child Adolesc Psychiatry; 2023 Oct; 32(10):2049-2056. PubMed ID: 35831669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of drugs for ADHD among adults-a multinational study among 15.8 million adults in the Nordic countries.
    Karlstad Ø; Zoëga H; Furu K; Bahmanyar S; Martikainen JE; Kieler H; Pottegård A
    Eur J Clin Pharmacol; 2016 Dec; 72(12):1507-1514. PubMed ID: 27586399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology, Treatment Patterns, Comorbidities, and Concomitant Medication in Patients with ADHD in Sweden: A Registry-Based Study (2018-2021).
    Giacobini M; Ahnemark E; Medin E; Freilich J; Andersson M; Ma Y; Ginsberg Y
    J Atten Disord; 2023 Oct; 27(12):1309-1321. PubMed ID: 37282510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trajectories of ADHD medication use before, during, and after pregnancy: A population-based study from Norway and Sweden.
    Srinivas C; Karlstad Ø; Stigum H; Furu K; Cesta CE; Reutfors J; Cohen JM
    Pharmacoepidemiol Drug Saf; 2023 Oct; 32(10):1152-1160. PubMed ID: 37309052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of Stimulants and Atomoxetine for Attention-Deficit/Hyperactivity Disorder among 5.4 Million Children Using Population-Based Longitudinal Data.
    Furu K; Karlstad Ø; Zoega H; Martikainen JE; Bahmanyar S; Kieler H; Pottegård A
    Basic Clin Pharmacol Toxicol; 2017 Apr; 120(4):373-379. PubMed ID: 27911044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.
    Nagy P; Häge A; Coghill DR; Caballero B; Adeyi B; Anderson CS; Sikirica V; Cardo E
    Eur Child Adolesc Psychiatry; 2016 Feb; 25(2):141-9. PubMed ID: 25999292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
    Elliott J; Johnston A; Husereau D; Kelly SE; Eagles C; Charach A; Hsieh SC; Bai Z; Hossain A; Skidmore B; Tsakonas E; Chojecki D; Mamdani M; Wells GA
    PLoS One; 2020; 15(10):e0240584. PubMed ID: 33085721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of Lisdexamfetamine Dimesylate Use in Children, Adolescents, and Adults with Attention-Deficit/Hyperactivity Disorder in Europe.
    Siffel C; Page M; Maxwell T; Thun B; Kolb N; Rosenlund M; von Bredow D; Keja J
    J Child Adolesc Psychopharmacol; 2020 Sep; 30(7):439-447. PubMed ID: 32315539
    [No Abstract]   [Full Text] [Related]  

  • 10. Trends in attention-deficit and hyperactivity disorder (ADHD) medications among children and young adults in Ireland: a repeated cross-sectional study from 2005 to 2015.
    Mac Avin M; Teeling M; Bennett KE
    BMJ Open; 2020 Apr; 10(4):e035716. PubMed ID: 32327478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and determinants of attention deficit/hyperactivity disorder (ADHD) medication use during pregnancy: Results from the Quebec Pregnancy/Children Cohort.
    Lemelin M; Boukhris T; Zhao JP; Sheehy O; Bérard A
    Pharmacol Res Perspect; 2021 May; 9(3):e00781. PubMed ID: 34003597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attention-Deficit/Hyperactivity Disorder Medications and Work Disability and Mental Health Outcomes.
    Taipale H; Bergström J; Gèmes K; Tanskanen A; Ekselius L; Mittendorfer-Rutz E; Helgesson M
    JAMA Netw Open; 2024 Mar; 7(3):e242859. PubMed ID: 38506810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases.
    Raman SR; Man KKC; Bahmanyar S; Berard A; Bilder S; Boukhris T; Bushnell G; Crystal S; Furu K; KaoYang YH; Karlstad Ø; Kieler H; Kubota K; Lai EC; Martikainen JE; Maura G; Moore N; Montero D; Nakamura H; Neumann A; Pate V; Pottegård A; Pratt NL; Roughead EE; Macias Saint-Gerons D; Stürmer T; Su CC; Zoega H; Sturkenbroom MCJM; Chan EW; Coghill D; Ip P; Wong ICK
    Lancet Psychiatry; 2018 Oct; 5(10):824-835. PubMed ID: 30220514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
    Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
    Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in Utilization Patterns among Medications in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: a 36-Month Retrospective Study Using the Korean Health Insurance Review and Assessment Claims Database.
    Bhang SY; Hwang JW; Kwak YS; Joung YS; Lee S; Kim B; Sohn SH; Chung US; Yang J; Hong M; Bahn GH; Choi HY; Oh IH; Lee YJ
    J Korean Med Sci; 2016 Aug; 31(8):1284-91. PubMed ID: 27478341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
    Stuhec M; Munda B; Svab V; Locatelli I
    J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of lisdexamfetamine dimesylate in children and adolescents with attention deficit/hyperactivity disorder.
    Najib J; Didenko E; Meleshkina D; Yusupov K; Maw K; Ramnarain J; Tabassum M
    Curr Med Res Opin; 2020 Oct; 36(10):1717-1735. PubMed ID: 32845786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic Management of Cognitive Disengagement Syndrome (CDS) and Implications for Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment: Emerging Treatments and Recommendations for Future Research.
    Wiggs KK; Froehlich TE; Becker SP
    CNS Drugs; 2023 Apr; 37(4):293-304. PubMed ID: 37061629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
    May DE; Kratochvil CJ
    Drugs; 2010; 70(1):15-40. PubMed ID: 20030423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.